# Hikal (NSE: HIKAL) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HIKAL · Pivot · prices to 21 Oct 2026

Hikal (NSE: HIKAL) closed at ₹209.70 on 21 Oct 2026. With a market capitalisation of ₹2,676 Cr, it ranks 1032nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −4.1% in FY26. Over the past year the share price has fallen 12.6%. Its 52-week range is ₹146.25 (30 Mar 2026) to ₹261.00 (4 Dec 2025); the last close is 19.7% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹400 Cr (+7.7% year on year) and net profit −₹7 Cr, on a consolidated basis. Promoters held 68.85% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹209.70 |
| Market cap | ₹2,676 Cr |
| ROE | −4.1% (FY26) |
| ROCE | 4.1% (FY26) |
| Debt to equity | 0.57 |
| 52-week high | ₹261.00 (4 Dec 2025) |
| 52-week low | ₹146.25 (30 Mar 2026) |
| 1-year return | −12.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹400 Cr | +7.7% | −₹7 Cr | — | −₹0.60 |
| Q4 FY26 | ₹517 Cr | −6.0% | ₹14 Cr | −71.3% | ₹1.17 |
| Q3 FY26 | ₹491 Cr | +11.8% | −₹6 Cr | −134.3% | −₹0.48 |
| Q2 FY26 | ₹316 Cr | −30.2% | −₹35 Cr | −290.7% | −₹2.83 |
| Q1 FY26 | ₹371 Cr | −8.0% | −₹22 Cr | −539.2% | −₹1.82 |
| Q4 FY25 | ₹550 Cr | +7.3% | ₹50 Cr | +47.8% | ₹4.07 |
| Q3 FY25 | ₹439 Cr | +0.1% | ₹17 Cr | +6.6% | ₹1.39 |
| Q2 FY25 | ₹453 Cr | +5.0% | ₹18 Cr | +45.6% | ₹1.48 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,860 Cr | ₹91 Cr |
| FY24 | ₹1,785 Cr | ₹70 Cr |
| FY23 | ₹2,023 Cr | ₹78 Cr |
| FY22 | ₹1,943 Cr | ₹161 Cr |
| FY21 | ₹1,720 Cr | ₹133 Cr |
| FY20 | ₹1,507 Cr | ₹84 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 68.85%
- Foreign institutions: 0.99%
- Domestic institutions: 7.24%
- Non-institutions: 22.93%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Shukra Pharma](https://app.pivotnow.in/stock/SHUKRAPHAR) | ₹68.40 | ₹3,007 Cr | 136.8 | — |
| [Advanced Enzyme Technologies](https://app.pivotnow.in/stock/ADVENZYMES) | ₹262.85 | ₹2,943 Cr | 17.4 | — |
| [Dishman Pharma](https://app.pivotnow.in/stock/DPC02) | — | ₹2,676 Cr | — | — |
| [Dr Agarwals Eye Hospital](https://app.pivotnow.in/stock/DRAGARWQ) | ₹5,083.50 | ₹2,457 Cr | — | — |
| [Alembic](https://app.pivotnow.in/stock/ALEMBICLTD) | ₹95.20 | ₹2,445 Cr | 7.7 | — |
| [Venus Remedies](https://app.pivotnow.in/stock/VENUSREM) | ₹1,796.10 | ₹2,401 Cr | 23.3 | — |

## Questions and answers

### What is the share price of Hikal today?

Hikal (NSE: HIKAL) last closed at ₹209.70 on 21 Oct 2026. Its 52-week high is ₹261.00 and its 52-week low is ₹146.25.

### What is the market cap of Hikal?

Hikal's market capitalisation is ₹2,676 Cr (₹2,676 Cr) at the 19 Oct 2026 close, ranking 1032nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Hikal?

Return on equity was −4.1% in FY26 and return on capital employed was 4.1% in FY26 (consolidated figures).

### Is Hikal a debt-free company?

No. Hikal's debt-to-equity ratio was 0.57 in FY26, with total debt of ₹373 Cr.

### What were Hikal's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Hikal reported revenue of ₹400 Cr, +7.7% year on year, and net profit of −₹7 Cr.

### How has Hikal stock performed over the last year?

Hikal's share price has fallen 12.6% over the past year, −4.9% over three months and −3.6% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Hikal?

As of 30 Jun 2026: promoters 68.85%, foreign institutions 0.99%, domestic institutions 7.24%, non-institutions 22.93%.

### Who are Hikal's competitors?

The listed Pharma & Healthcare companies closest to Hikal by market cap are Shukra Pharma, Advanced Enzyme Technologies, Dishman Pharma, Dr Agarwals Eye Hospital, Alembic and Venus Remedies.

### Is Hikal a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Hikal's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HIKAL against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.